How Sonic Healthcare grew from a Sydney pathology practice into a $9.6bn global diagnostics group through 100+ acquisitions, led by one CEO for 30+ years.
Sonic Healthcare Limited (ASX: SHL) provides medical laboratory testing, diagnostic imaging and clinical services across Australia, the USA, Germany, the UK, Belgium, Poland, Switzerland and New Zealand.
Sonic Healthcare has built one of the world's largest pathology networks through a disciplined buy-and-hold acquisition strategy. The company targets founder-owned or smaller operator pathology and radiology practices, acquires them at reasonable multiples, and retains the medical practitioners under a decentralised model it calls "Medical Leadership".
As of 2026, Sonic Healthcare operates in eight countries with over 600 laboratories and collection centres. The business generates ~$9.6bn in annual revenue. The company continues to pursue bolt-on acquisitions, particularly in Europe and the United States.
An investor who participated in Sonic Healthcare's 1987 listing at ~$0.20 per share would have seen a share price of ~$25 by 2025, representing a capital return of over 12,000%. Including dividends (paid since the early 1990s), total returns have been substantially higher.
April 2026, when this case study was first published. Figures and company status reflect information available at that date.
Sonic Healthcare was founded in 1987 when a group of Sydney-based pathologists listed their practice on the Australian Securities Exchange. The business began as a small pathology services company operating primarily in New South Wales.
The defining figure in Sonic Healthcare's history is Dr Colin Goldschmidt, who has served as Managing Director and CEO since 1993. Goldschmidt is a trained pathologist with a medical degree and an MBA. His dual background in medicine and business has shaped Sonic's unique operating philosophy: that diagnostic businesses perform best when they are run by clinicians, not administrators.
Goldschmidt has remained at the helm for over 30 years. Under his leadership, Sonic grew from a small Australian practice into a globally listed diagnostics company with operations spanning eight countries. His long tenure is unusual in corporate Australia and reflects a board that has consistently backed his acquisition-led strategy.
Sonic Healthcare's stated philosophy is "Medical Leadership": the belief that diagnostic businesses are best run by clinicians. The company positions pathologists and radiologists at the top of its management structure in each geography.
Sonic Healthcare generates revenue by performing medical tests and diagnostic imaging. Pathology revenue comes from testing biological specimens (blood, tissue, urine etc.) and reporting the results to clinicians and patients. Radiology revenue comes from diagnostic imaging including X-ray, MRI, CT and ultrasound. The mix of revenue varies by geography, but pathology makes up the majority of group revenue.
Revenue is largely recurring. Patients return for tests on a regular basis, driven by chronic disease management, routine health checks, hospital in-patient needs and specialist referrals. This recurring nature makes the business highly cash generative and relatively predictable, which in turn supports a high level of debt capacity for acquisitions.
The pathology and radiology markets are fragmented. Many of the best diagnostic businesses are still owned by the founding medical practitioners who built them. These owners face a common problem: succession. As they approach retirement, they need a buyer who will pay fair value, maintain the practice's culture, and give them an exit that allows them to stay involved in medicine if they choose.
Sonic's acquisition strategy is built to solve this problem. It offers succession planning to physician owners at fair valuations, retains the brand and culture, keeps the medical leaders in place, and then integrates back-office functions such as IT, procurement, billing and compliance to improve margins. This model creates a virtuous cycle: Sonic's reputation as a respectful acquirer means it sees more deals, often without competitive auction processes.
Each acquisition adds scale, which improves purchasing power for supplies and equipment, allows shared IT infrastructure costs to be spread over a larger revenue base, and creates geographic density that improves the efficiency of specimen collection logistics. The result is that margins tend to improve over time as scale increases.
Sonic Healthcare's stated acquisition discipline centres on paying reasonable EBITDA multiples and targeting a return on invested capital above its cost of capital within a reasonable timeframe. The company has generally targeted acquisitions in the 6× to 10× EBITDA range for standalone businesses, with larger transactions in more developed markets sometimes reaching slightly higher multiples.
Sonic sources acquisitions through multiple channels. The most important channel is its reputation. Because Sonic has a 30-year track record of retaining brands, keeping medical leaders in place, and paying agreed prices without post-completion re-trading, it receives inbound approaches from owners looking for a buyer. This gives Sonic a significant advantage over private equity or less well-known trade acquirers who may face more competitive auction processes.
Sonic's acquisition model is not a standard corporate integration. The acquired business retains its name, its clinical leaders and its patient relationships. What changes is the back office. Sonic integrates billing, IT, procurement, HR and compliance functions into its existing country infrastructure. This typically takes 12 to 24 months after completion.
Since listing in 1987, Sonic Healthcare has completed over 100 acquisitions across eight countries. The acquisitions have spanned pathology laboratories, radiology practices and associated diagnostic services. The total capital deployed in acquisitions is estimated to exceed $5bn over the company's history. The pace of acquisition has increased significantly since the early 2000s as Sonic moved aggressively into international markets.
Key patterns in Sonic's acquisition history include a consistent preference for controlling stakes (full acquisitions), a focus on retaining the target brand and clinical leadership, and a geographic strategy of building density within a market before moving to a new one. The company rarely makes minority investments.
Sonic's first decade was spent building dominance on the Australian eastern seaboard. Douglas Hanly Moir Pathology (~$30m), Sullivan Nicolaides Pathology (~$70m) and Dorevitch Pathology (~$80m) gave the company market-leading positions in NSW, Queensland and Victoria respectively. Each retained its brand and clinical leadership, the template that every subsequent deal would follow. Clinpath in South Australia completed the national footprint, transforming Sonic from a small Sydney practice into Australia's largest pathology operator.
The 2001 acquisition of Clinical Pathology Laboratories in Texas (~US$100m) was Sonic's first international move, establishing the platform for Sonic Healthcare USA. Germany followed from 2003, where the physician-owned, insurance-funded lab structure closely mirrored the Australian market Sonic had already consolidated. Medlab in New Zealand (~NZ$110m) and CBLPath in New York (~US$60m) were also added during this period. By 2007, Sonic operated in four countries and was generating meaningful international revenue for the first time.
Bioscientia in 2010 was the most consequential acquisition in Sonic's history. Priced at ~€200m and funded partly through a $350m equity raise, it made Sonic one of Germany's two largest pathology operators overnight. The UK was entered in 2012 via NHS-outsourced laboratory contracts. Belgium and Ireland followed in 2014. Concurrent bolt-ons across the USA added density to the American network. By 2015, Sonic was generating ~$4.2bn in revenue across six countries.
Switzerland was added in 2017, offering high private-payer margins well above the German and UK markets. The Pathology North contract in NSW extended Sonic's Australian presence into public hospital services. COVID-19 from 2020 to 2022 was not an acquisition story (revenue nearly doubled to ~$10.5bn from PCR testing volumes), but the exceptional cash flows allowed Sonic to cut debt and fund further bolt-ons in Germany and the USA. From 2023, the company returned to its steady-state acquisition cadence as COVID revenues unwound.
Sonic Healthcare has funded its acquisition program through a combination of operating cash flow, debt and periodic equity raises. The business is highly cash generative. Pathology and radiology produce strong and predictable free cash flow, which allows Sonic to carry a meaningful level of debt without undue financial risk.
The company's strategy was to raise equity in small chunks aligned with deals, rather than one enormous fundraising, thereby managing dilution and deploying funds quickly into earning assets. Investors were generally supportive, as each raise was accompanied by news of earnings-accretive acquisitions. Sonic often structured these as private placements or rights issues at a slight discount to the market price, attracting both existing and new shareholders.
Chart (hbars): Sonic Healthcare equity raises ($m)
Source: Deal Advisory analysis. Uses: initial listing and working capital (1987); Sullivan Nicolaides and Dorevitch (1997); US entry via Clinical Pathology Laboratories (2001); German and NZ expansion (2004); Bioscientia (2010); European bolt-ons and balance sheet flexibility (2015).
Sonic has used a range of debt instruments including Australian and US dollar-denominated syndicated bank facilities, US Private Placement (USPP) notes, and Euro Medium Term Notes (EMTN) for its European operations. This currency matching between debt and earnings reduces foreign exchange risk on the balance sheet.
Net debt to EBITDA has typically been maintained in the 1.5× to 2.5× range during periods of active acquisition, and the company has generally been able to reduce leverage quickly given the strength of its operating cash flows. During the COVID-19 period, the exceptional earnings allowed Sonic to reduce net debt significantly, which created balance sheet capacity for acquisitions in 2022 and beyond.
Sonic has not relied heavily on vendor financing or earnout structures. It typically pays cash at completion, which is another reason it is attractive to vendors. The certainty of a cash payment reduces execution risk for selling physicians who may be approaching retirement.
Each major acquisition has added immediately to revenue and EBITDA. The quality of earnings added has generally been high: acquired businesses tend to have recurring revenue streams, predictable margins, and limited capital intensity beyond the initial purchase price.
The main financial risk from acquisitions has been the amortisation of acquired intangibles (customer lists, brand value, laboratory licences), which reduces reported NPAT but does not represent a cash outflow. This is a point that investors in Sonic have historically needed to understand: reported earnings understate underlying cash earnings due to non-cash amortisation charges on acquisition intangibles.
Chart (bars): Sonic Healthcare revenue by financial year
Chart (bars): Sonic Healthcare EBITDA by financial year
Source: Deal Advisory analysis. FY22 includes COVID-19 PCR testing.
Share prices have gone from 20c at listing (market cap of ~$30m) to ~$23 in January 2026 (market cap of $9.5bn). Acquisitions have been the primary driver of share price appreciation over Sonic's history. Every significant acquisition announcement has generally been well received by the market, reflecting investor confidence in Sonic's track record of execution. The Bioscientia deal in 2010, for example, was accompanied by a well-supported equity raise and drove a re-rating of the stock as investors recognised Sonic was building genuine global scale in pathology.
Sonic Healthcare has paid dividends consistently since the early 1990s. The dividend has grown broadly in line with earnings, and the company targets a payout ratio of ~60–70% of NPAT. At current price levels, the forward dividend yield is ~3.4–4.5% fully franked for Australian investors.
Sonic has never materially strayed from pathology and radiology. It has not acquired hospitals, GP clinics, pharmacies or consumer health businesses. This focus means every acquisition deepens the company's core expertise, adds to its procurement scale, and is integrated by a management team with relevant experience. Acquirers that diversify into adjacent markets typically discover that integration complexity and management distraction outweigh the revenue diversification benefits.
The most valuable acquisitions are typically the ones that never go to a competitive auction. Sonic's 30-year track record of keeping promises to vendors (retaining brands, keeping medical leaders, paying agreed prices) means it receives inbound interest from practice owners who want to sell on their terms. Building this reputation takes years and requires consistent behaviour through cycles.
Pathology and radiology businesses have some of the most predictable revenue streams in healthcare. This predictability means they can support more debt than cyclical businesses, which allows acquirers to move faster without diluting equity holders through repeated capital raises. Identifying industries with this characteristic (recurring, non-discretionary demand) helps massively with a successful consolidation strategy.
Sonic's Medical Leadership model is a genuine structural differentiator. By positioning clinicians as the leaders of acquired businesses, Sonic reduces integration risk, retains the relationships that create revenue, and makes itself a preferred buyer in a market where vendors care deeply about what happens to their patients and staff after a sale. Any acquirer seeking to replicate this strategy needs to develop a credible, authentic operating philosophy that resonates with the type of vendors they are targeting. A model that looks genuine but is not will be rejected by experienced medical professionals quickly.
Sonic's COVID years generated exceptional cash flows from PCR testing. The business used this windfall wisely, paying down debt and funding further acquisitions, but the subsequent unwinding of COVID revenues created a period of earnings decline and share price weakness.
Lesson: this was not a strategic error by Sonic. Investors and management should model the base business independently of exceptional revenue periods, and avoid valuing acquisitions or levering the balance sheet based on peak earnings that may be temporary.
Sonic's acquisition strategy did not succeed because of the strategy alone; it succeeded because the same person executed it for over 30 years. Colin Goldschmidt has been CEO since 1993. That continuity meant the Medical Leadership philosophy was never diluted by a new executive team with different priorities. Good leaders do not just make better decisions; they make the same good decisions consistently, and that consistency is what turns a strategy into a compounding asset.
Get a free, data-backed estimate of what your business could be worth.
Get your free appraisal
